An interventional study of Ondansetron (Zofran) and Diphenhydramine (Benadryl) in Itching, sponsored by United States Army Institute of Surgical Research. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2008-07-28.
Sponsored by United States Army Institute of Surgical Research · Not applicable, Interventional, and Treatment
The purpose of this study is to see if a drug called ondansetron (Zofran) controls itching from healing burn wounds as well or better than the usual drug used, diphenhydramine (Benadryl).
A clear mechanism or cause for pruritus in patients recovering from burn has not been delineated.
While the exact mechanisms/pathways for itching are currently unclear, histamine antagonism appears to be the most popular treatment. Whether histamine antagonism works predominantly via peripheral inhibition or central sedation is uncertain. By treating another intermediary in the pruritus cascade, it may be possible that an alternate treatment could be used while eliminating some of the unwanted side effects of antihistamine at the same time.
354 studies on the registry are indexed under Pruritus; 74 are open to participants now.
This study's enrollment of 36 is below the median of 60 across 294 interventional studies indexed under Pruritus.
Browse Pruritus studies →United States Army Institute of Surgical Research is the lead sponsor of 24 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Drug: Ondansetron (Zofran) · Drug: Diphenhydramine (Benadryl)
Ondansetron will have a greater ability to control pruritus in burn patients who are undergoing wound healing when compared to the standard of care, diphenhydramine.
Time frame: 14 days
This study is completed, as verified in Jul 2008. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
United States Army Institute of Surgical Research